SurrogateBMA (Q5977130): Difference between revisions
From MaRDI portal
Removed claims |
Added link to MaRDI item. |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Property / programmed in | |||
| Property / programmed in: R / rank | |||
Normal rank | |||
| Property / depends on software | |||
| Property / depends on software: R / rank | |||
Normal rank | |||
| Property / depends on software: R / qualifier | |||
software version identifier: ≥ 3.5.0 | |||
| Property / MaRDI profile type | |||
| Property / MaRDI profile type: MaRDI software profile / rank | |||
Normal rank | |||
| links / mardi / name | links / mardi / name | ||
Latest revision as of 20:10, 12 March 2024
Flexible Evaluation of Surrogate Markers with Bayesian Model Averaging
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | SurrogateBMA |
Flexible Evaluation of Surrogate Markers with Bayesian Model Averaging |
Statements
Provides functions to estimate the proportion of treatment effect explained by the surrogate marker using a Bayesian Model Averaging approach. Duan and Parast (2023) <doi:10.1002/sim.9986>.
0 references
1 February 2024
0 references
expanded from: GPL (≥ 2) (English)
0 references
